Summary of Significant Accounting Policies (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of Accounts Receivable |
The
following table presents the changes in the Company’s allowance for doubtful accounts:
Schedule of Accounts Receivable
| | |
| | |
| Balance as of December 31, 2025 | |
$ | 69,641 | |
| Provision | |
| 6,125 | |
| Write-offs | |
| - | |
| Recoveries | |
| - | |
| Balance as of March 31, 2026 | |
$ | 75,766 | |
|
| Schedule of Fair Value on Recurring Basis |
The
following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company’s assets that are
measured at fair value on a recurring basis as of March 31, 2026:
Schedule
of Fair Value on Recurring Basis
| | |
Quoted
Prices in
Active Markets
(Level 1) | | |
Significant
Other
Observable Inputs
(Level 2) | | |
Significant
Other
Unobservable
Inputs (Level 3) | |
| Assets: | |
| | | |
| | | |
| | |
| Note
receivable | |
$ | - | | |
$ | - | | |
$ | 5,029,770 | |
The following table presents, for each of the
fair value hierarchy levels required under ASC 820, the Company’s assets and liabilities that are measured at fair value on a
recurring basis as of December 31, 2025:
| | |
Quoted
Prices in
Active Markets
(Level 1) | | |
Significant
Other
Observable Inputs
(Level 2) | | |
Significant
Other
Unobservable
Inputs (Level 3) | |
| Assets: | |
| | | |
| | | |
| | |
| Note receivable | |
$ | - | | |
$ | - | | |
$ | 5,029,770 | |
| Liabilities: | |
| | | |
| | | |
| | |
| Warrant liability | |
$ | - | | |
$ | - | | |
$ | 1,881,078 | |
|
| Schedule of Changes in Fair Value |
The
following table presents the changes is the fair value of the Level 3 assets and liabilities:
Schedule of Changes in Fair Value
| | |
Note
receivable | | |
Warrant
liability | |
| Fair value as of December 31, 2025 | |
$ | 5,029,770 | | |
$ | 1,881,078 | |
| Change in valuation | |
| - | | |
| 3,790,225 | |
| Reclassification
to equity |
|
|
- |
|
|
|
(5,671,303 |
) |
| Balance as of March 31, 2026 | |
$ | 5,029,770 | | |
$ | - | |
|
| Schedule of Deferred Revenue |
The
following table presents the changes in the Company’s deferred revenue:
Schedule of Deferred Revenue
| | |
| | |
| Balance as of December 31, 2025 | |
$ | 721,897 | |
| Additions to deferred revenue | |
| 1,892,610 | |
| Revenue recognized from
deferred revenue | |
| (1,889,015 | ) |
| Balance as of March 31, 2026 | |
$ | 725,493 | |
|
| Schedule of Earnings Per Share Basic and Diluted |
Schedule of Earnings Per Share Basic and Diluted
| | |
2026 | | |
2025 | |
| | |
Three
Months Ended March
31, | |
| | |
2026 | | |
2025 | |
| Net loss (numerator) | |
$ | (5,539,351 | ) | |
$ | (17,403,586 | ) |
| Basic and diluted weighted-average
number of common shares outstanding (denominator) | |
| 1,637,859 | | |
| 5,010 | |
| Basic and diluted net
loss per common share | |
$ | (3.38 | ) | |
$ | (3,473.93 | ) |
|
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share |
The
Company has excluded the following dilutive securities from the calculation of fully diluted shares outstanding because the result would
have been anti-dilutive:
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
| | |
2026 | | |
2025 | |
| | |
As
of March 31, | |
| | |
2026 | | |
2025 | |
| Options | |
| 9,123 | | |
| 68 | |
| Convertible notes and interest | |
| 498,086 | | |
| 5,264 | |
| Convertible preferred stock |
|
|
66,667 |
|
|
|
- |
|
| Warrants | |
| 2,051,770 | | |
| 20,644 | |
| Total | |
| 2,625,646 | | |
| 25,976 | |
|